Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) was the recipient of unusually large options trading on Wednesday. Traders bought 7,487 call options on the company. This represents an increase of approximately 54% compared to the typical volume of 4,876 call options.

Omeros News Summary

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 results showed a swing to GAAP net income of $86.5M ($1.22/share) vs. a loss a year earlier; full-year 2025 loss narrowed materially — this reversal to profitability supports the rally. Business Wire Release
• Positive Sentiment: Omeros reported EPS of $3.14 for the quarter, well above analyst expectations (consensus around -$0.55), a significant beat that likely drove short-term buying. MarketBeat EPS Report
• Positive Sentiment: Management announced YARTEMLEA is expected to be financially self-sustaining in 2026 and reiterated a goal of positive company-level cash flow in 2027, improving visibility on funding needs. Seeking Alpha: YARTEMLEA Outlook
• Positive Sentiment: After-hours reporting of a Novo Nordisk-related deal windfall and continued optimism around drug launches added to sentiment that near-term cash and milestone income could be stronger than feared. MSN: Novo Nordisk Deal
• Neutral Sentiment: Earnings call transcript and highlights provide more detail on strategic deals, FDA pathways and commercialization plans — useful for modeling but already priced in by some traders. Earnings Call Transcript
• Neutral Sentiment: Market technicals: the stock recently moved above its 200-day moving average, a signal that may attract technical buyers but not a fundamental guarantee. Technical Note
• Neutral Sentiment: Short-form earnings snapshots and sector articles summarize the quarter and management commentary — helpful for headlines but add limited new info beyond the press release and call. Yahoo Finance Highlights

Omeros Trading Up 15.3%

Shares of Omeros stock traded up $1.61 during trading hours on Wednesday, reaching $12.17. The stock had a trading volume of 2,446,460 shares, compared to its average volume of 1,486,050. The firm has a market capitalization of $863.07 million, a price-to-earnings ratio of -6.01 and a beta of 2.45. Omeros has a 1 year low of $2.95 and a 1 year high of $17.65. The firm has a 50 day simple moving average of $11.40 and a two-hundred day simple moving average of $9.76.

Analysts Set New Price Targets

A number of research firms have recently weighed in on OMER. HC Wainwright boosted their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research note on Tuesday, January 27th. Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Insider Buying and Selling

In related news, CAO David J. Borges sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Omeros

Several institutional investors have recently bought and sold shares of OMER. Farther Finance Advisors LLC increased its position in shares of Omeros by 16.5% in the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 1,004 shares in the last quarter. State of Wyoming acquired a new position in shares of Omeros during the 4th quarter valued at $25,000. AQR Capital Management LLC boosted its position in Omeros by 7.2% during the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 1,532 shares during the period. ProShare Advisors LLC increased its holdings in Omeros by 12.1% in the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 1,637 shares in the last quarter. Finally, Cerity Partners LLC increased its holdings in Omeros by 6.1% in the 4th quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company’s stock valued at $523,000 after purchasing an additional 1,750 shares in the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.